newsoncologyselumetinib
SARC031 Trial: Why Combined MEK and mTOR Inhibition Failed to Translate from Mice to Men in MPNST
By MedXY|Jan 13, 2026
The SARC031 Phase 2 trial evaluated selumetinib and sirolimus for advanced MPNST. Despite strong preclinical rationale, the combination showed minimal clinical benefit, though correlative studies on cfDNA and PET imaging offer vital insight
